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Abstract: This is a short review focusing on leptin immunoin-
flammatory mechanisms that ultimately may contribute to lung
cancer development. We explored the complex and intricate inter-
action of leptin with immune cells to propose a pathway of inflam-
mation-associated lung cancer development.
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IMMUNOINFLAMMATORY RESPONSE
AND LUNG CANCER
Immune cells constitute a critical component of host
response to cancer,1 although their role in cancer pathogen-
esis remains incompletely established. Epidemiological data
indicate that chronic inflammation increases the risk of ma-
lignant transformation2 and, therefore, that unresolved host
immune reactivity may promote tumor development.3 In fact,
persistent or recurrent immunoinflammatory up-regulation
may induce or influence susceptibility to carcinogenesis by
some known mechanisms (Fig. 1).4
Most lung cancer patients are smokers,5 and tobacco
consumption is a well-established risk factor.6 A chronic
inflammatory state is known to correlate with the decline in
lung function among smokers7,8 and with lung cancer etio-
pathogenesis.9 Chronic cigarette smoking retards mucociliary
clearance of foreign particulates and secretions that favor a
persistent inflammation, whereas the inhaled particles evoke
vigorous lung and airway inflammatory responses.10–12 Initi-
ation of the immunoinflammatory lung response is induced
by exposure to inhaled antigenic particles and is followed by
an expression pattern of chemokines and cytokines that may
be influenced by the individual genetic background.13,14 This
mechanism may predispose a patient to an amplified and
longer immune response. The role of chemokines in lung
cancer biology has been highlighted in a previous review.15
LEPTIN, INFLAMMATION, AND LUNG CANCER
Investigators have found that a functional polymor-
phism in the leptin gene (LEP-2548 G/A) was associated with
increased risk for developing non-small cell lung cancer
(odds ratio, 1.97; 95% confidence interval, 1.13–3.43) and to
earlier onset of disease, and that carriers of the risk genotype
simultaneously smokers had even higher risk for developing
cancer of the lung (odds ratio, 4.82; 95% confidence interval,
1.05–22.17).16 These results support leptin’s role in exacer-
bating existing cigarette smoke-induced lung inflammation
that may lead to increased amplitude and duration of reaction,
which has a major role in lung cancer pathogenesis.
Leptin is an adipocytokine that has been consistently
implicated in lung physiology and pathophysiology. It is
involved in fetal lung development and in adult normal lung
cells’ physiology or malignant proliferation.17–19 Besides a
possible direct effect of leptin in normal and tumor lung cells,
most importantly, there is strong evidence of leptin’s up-
regulatory role in the immunoinflammatory system,20 sup-
porting its role as a prominent interplay between inflamma-
tion and lung cancer (Figure 1). It is now well established that
fat depots’ function goes beyond structural, metabolic, and
heat-insulating properties because of cytokines, growth fac-
tors, and hormone production that may prolong the pro-
inflammatory microenvironment.
LEPTIN, INNATE IMMUNITY, AND CANCER
Although the immune surveillance hypothesis has re-
ceived some experimental support, the net effect of inflam-
mation and/or innate immune system activation is stimulation
of tumor growth in most cases.21 Leptin affects both innate
and adaptive immunity. In innate immunity, leptin directly
and indirectly modulates the activity and function of neutro-
phils by increasing chemotaxis and production of oxygen
radicals,22 increases phagocytosis by monocytes/macro-
phages, and activates and promotes macrophage cell chemo-
taxis.23 Cumulatively, it was shown that recombinant human
leptin administration increased both C-reactive protein and
P-selectin,24 whereas an association was observed between
the concentration of VCAM-1 and ICAM-1 and circulating
leptin levels.25,26 These evidences support an indirect role for
leptin in chemotaxis and, consequently, in attraction of in-
flammatory cells through an action in adhesion molecules,
further increasing the magnitude of inflammation.
The inflammatory process initiated by infection, cellu-
lar damage, tumor cells, reactive oxygen species production,
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inhaled particles from tobacco, or environment pollutants
stimulates the synthesis of interleukin (IL)-1, IL-6, leptin, and
tumor necrosis factor (TNF) by macrophages and stromal and
endothelial cells.27,28 These molecules are partially responsi-
ble for the expression of acute-phase inflammatory response
elements, such as cyclooxygenase-2, nuclear factor B, and
C-reactive protein,29 and are associated with the induction of
leukocyte recruitment and activating-adhesion molecules,
P-selectin, E-selectin, VCAM and ICAM.28,30 Activated leu-
kocytes produce large quantities of reactive oxygen species
that will cause oxidative damage to surrounding cells and en-
hance risk for inflammation-mediated cytotoxicity and DNA
damage in normal cells. The role of leptin in up-regulating
reactive oxygen species production through an effect in
monocytes or indirectly in endothelial cells by an increase in
monocyte-chemoattractant protein 1 is well known.31,32 Re-
active oxygen species derived from inflammation is an im-
portant endogenous carcinogenic factor, which is increased
by long-term chronic inflammation.
Santos-Alvarez et al.33 observed a stimulatory effect of
leptin on peripheral blood mononuclear cell production of
TNF and IL-6. Furthermore, leptin’s role in peripheral blood
mononuclear cell proliferation and activation is mediated by
activation of the leptin receptor in these cells,34 inducing a
pattern of cytokine release compatible with the induction of
a T-helper 1 immune response,35 which is associated with a
negative prognostic factor in patients with non-small cell lung
cancer. Leptin mediates the up-regulation of dendritic cells’
function and survival and decreases production of IL-10,
which further contributes further to T-helper 1 immune phe-
notype.36 Simultaneously, leptin up-regulates the secretion of
IL-1, IL-6, IL-12, TNF, and MIP-1 by dendritic cells.36
Activation of the inhibitor of nuclear factor-B kinase
-dependent nuclear factor-B molecular pathway is a mo-
lecular mechanism that connects inflammation and cancer. Its
activation increases tumor growth and progression in differ-
ent cell types through activation of gene targets of pro-
inflammatory cytokines and chemokines, such as TNF, IL-1,
FIGURE 1. Leptin’s role in immunoinflamatory-mediated lung cancer development. After exposure to inhaled antigens (e.g.,
smoke particles) follows acute inflammation that under normal circumstances is self-limited. However, depending on the mag-
nitude and duration of exposure to pro-inflammatory inhaled antigens and on the individual’s genetic background (polymor-
phisms in genes that express pro-inflammatory molecules), the inflammatory reaction may last longer and/or may be in-
creased. Leptin may have a central role in chronic inflammation development and maintenance of chronic inflammation,
through autocrine, paracrine, and endocrine mechanisms. There is a broad range of action for leptin in immune cells. Leptin
stimulates and activates neutrophils, macrophages, peripheral blood mononuclear cells, dendritic cells, and T cells, whose
products, ultimately, may induce chronic inflammation and lung cancer carcinogenesis. Th0  naive T cell, Th1  T helper 1,
Th2  T helper 2, NF-B  nuclear factor B, TNF  tumor necrosis factor-, VEGF  vascular endothelial growth factor,
PLA2  phospholipase A2, LKTs  leukotrienes, PGs  prostaglandins, IFNg  interferon-, COX-2  cyclooxygenase 2,
iNOS  inducible nitric oxide synthase, NO  nitric oxide, CSF  colony stimulating factor, ROS  reactive oxygen species,
RNS  reactive nitrogen species, PBMCs  peripheral blood mononuclear cells.
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and IL-6.37 The up-regulation of immunomodulators TNF,
IL-1, IL-6, and prostaglandin E2 through leptin via the nu-
clear factor-B pathway38 further strengthens the up-regu-
lated pro-inflammatory profile in the tumor microenviron-
ment. Furthermore, TNF and IL-1 stimulate leptin production
by adipocytes,39,40 further contributing to prolonged leptin-
induced inflammation.
After leptin’s stimulatory effect, macrophages also in-
crease the production of the pro-inflammatory enzyme cyclo-
oxygenase 2 and their products leukotriene (LKT) B4 and
prostaglandin (PG) E2, and augments inducible nitric oxide
synthase (iNOS) activity.41,42 Production of reactive nitrogen
species (RNS) in response to inflammation-induced iNOS
overexpression might induce generation and accumulation of
additional mutations that drive tumor progression.43 Several
studies support a stimulatory action of leptin in endothelial
NOS (eNOS) and inducible NOS (iNOS) activities, which
results in increased NO production by adipocitic and endo-
thelial cells.44,45 Raso et al42 showed that leptin is a potent
synergistic factor that cooperates with IFN- to increase the
expression of iNOS and cyclooxygenase 2. The cyclooxygen-
ase-2 enzyme up-regulates the production of the vasoactive
prostaglandins (PGs) and leukotrienes (LKTs) responsible for
increasing the amount of local vasodilation and vasoperme-
ability, and cumulatively, for enhanced inflammation through
leukocytes accumulation. The PGs also inhibit apoptosis and
stimulate angiogenesis and invasiveness.46 As a result of
chronic inflammation, constant exposure to cyclooxygenase
2-derived prostaglandins may also enhance carcinogenic risk
by reducing apoptosis and increasing the likelihood of mutant
cell survival and cancer development.
LEPTIN, ADAPTIVE IMMUNITY, AND CANCER
Apparently, T cells may also contribute to tumor
growth because, in the progression phase, they are the main
source of IL-6,47 and their overall contribution might depend
on the balance between tumor-promoting cytokines, such as
IL-6, and tumor-suppressor cytokines, such as IL-10 and
TGF-.37 Leptin, which increases IL-6 production and de-
creases IL-10 secretion, provides an interesting clue to the
understanding of leptin’s association with inflammation and
cancer, although much research in inflammatory cancer mod-
els is required to clarify this issue.
In adaptive immunity, leptin affects the generation,
maturation, and survival of thymic T cells by reducing their
rate of apoptosis.48 Leptin orients naive T-cell proliferation
and differentiation to TH1 phenotype36 and promotes the
switch toward TH1 immune responses on memory T cells by
increasing IFN and TNF secretion and stimulating the pro-
duction of IgG2 by B cells.49 The TH1/TH2 cytokine bal-
ance is preserved in normal individuals, but during inflam-
mation, the imbalance in the TH1/TH2 cytokine response
overcomes. In patients with non-small cell lung cancer, a high
TH1/TH2 ratio in peripheral blood is a negative prognostic
factor.50
SUMMARY
Recent developments in leptin immunological pathways
suggest a previously unappreciated complexity of cancer cell-
normal cell-immunoinflammatory cell cross-talk. This interac-
tion found in the inflammatory medium may deregulate and
increase the magnitude and duration of inflammation, promoting
tumor development. Leptin, a pleiotrophic hormone synthesized
mainly by adipocytes, may be an important interplay between
immunoinflammatory up-regulation and lung cancer develop-
ment, warranting further studies in this field.
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